Results 81 to 90 of about 122,325 (212)

Driving HCV Elimination Through Dedicated Hospital-Based Teams and Pathways: A Retrospective and Prospective Study. [PDF]

Liver Int
Torre P, Serretiello E, Di Siervi G, Vaccaro E, Sarcina T, Festa M, Folliero V, Masarone M, Franci G, Persico M.   +9 more
europepmc   +1 more source

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort

Alimentary Pharmacology &Therapeutics, EarlyView.
In 1,756,593 young adults, a generalized boosted survival model predicted incident HCC with strong discrimination (1‐year AUROC 0.945; 5‐year 0.825). The 1‐year horizon uniquely targets an imaging‐silent, pre‐diagnosis window, showing routine clinical signals can flag otherwise undetectable risk.
Seogsong Jeong, Gi‐Ae Kim, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Keon Wook Kang, Hwamin Lee, Won Kim   +7 more
wiley   +1 more source

Incidence of HIV and HCV Among People Who Inject Drugs in Montreal, Canada: Data From the HEPCO Longitudinal Cohort Study, 2011-2025. [PDF]

J Viral Hepat
Kleiner BB, Meconnen M, Azar M, Minoyan N, Zang G, Artenie A, Martel-Laferrière V, Jutras-Aswad D, Bruneau J, Larney S.   +9 more
europepmc   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, EarlyView.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity

Rheumatology &Autoimmunity, EarlyView.
Jiekai Tan, Fanlei Hu, Chuanhui Xu
wiley   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence. [PDF]

Am J Epidemiol
LaHood A, Robins J, Stagg HR, Sauer S, Ahmed S, Bastard M, Guglielmetti L, Hewison C, Huerga H, Isani AK, Khan P, Khan U, Lomtadze N, Mamsa S, Melikyan N, Mitnick CD, Rich ML, Seung K, Siddiqui MR, Skrahina A, Stambekova A, Tefera GB, Franke MF.   +22 more
europepmc   +1 more source

Socioeconomic Inequalities in Receipt of Curative‐Intent Treatment and Survival After Surveillance‐Detected Hepatocellular Carcinoma: A Nationwide Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Socioeconomic inequalities in receipt of curative‐intent treatment and survival persist among individuals with surveillance‐detected HCC within a universal healthcare system. These findings suggest that surveillance alone is insufficient to ensure equitable outcomes and highlight the need for strategies addressing social determinants across the care ...
Hannes Hagström, Jeffrey V. Lazarus, Malin Sternby Eilard, Adam Bergman, Magnus Rizell, Per Sandström, Juan Vaz   +6 more
wiley   +1 more source

Intraoperative pain sensitivity and aqueous humor inflammatory cytokine profiles in hepatitis C virus antibody-positive cataract patients. [PDF]

Int Ophthalmol
Zhang JS, Wang JD, Li M, Mao YY, Liu JY, Xu J, Wan XH.   +6 more
europepmc   +1 more source

Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain

Alimentary Pharmacology &Therapeutics, EarlyView.
Clinical burden of symptomatic HEV‐3 infection in southern Spain. Between 2022 and 2025, 1124 patients with acute hepatitis, defined as ALT ≥ 3 times the upper limit of normal and negative screening for HAV, HBV, HCV, EBV and CMV, were evaluated in Andalusia.
María Casares‐Jimenez, Claudia Ferreira‐Tata, Isabel Viciana, Carolina Freyre‐Carrillo, Pedro Lopez‐Lopez, Ana Belen Perez, Berta Becerril‐Carral, Ana Fuentes, Juan Macías, Lucia Rios‐Muñoz, Francisco Franco‐Alvarez de Luna, María Teresa Cabezas‐Fernandez, Diana Corona‐Mata, Antonio Rivero‐Juarez, Antonio Rivero   +14 more
wiley   +1 more source